Hungarian Investment Promotion Agency

Supported by the HIPA Hungarian Investment Promotion Agency, the EUR 6.56 million investment aims to introduce an industry-scale, automated technology to produce radiopharmaceuticals, that is faster, and more efficient and accurate than the currently dominant manual, small-dose method.

The project will create 30 new jobs, most of them for highly qualified professionals in R&D and advanced technology fields. The new technology could set a new industry standard and strengthen Hungary’s position as a regional hub in nuclear medicine.

Radiopharmaceuticals are primarily used in diagnostics. The radioactive preparations allow for the examination of various organs, assisting doctors in identifying malignant conditions and monitoring effects of treatments.

Medi-Radiopharma was founded in 1995 and has contributed to tens of millions of diagnostic procedures worldwide. The company employs around 100 people, generates more than 90 percent of its revenue from exports, and sells its products in over 80 countries.